← Eichor
Study identifier: NCT05198830 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

Condition: Lung Adenocarcinoma · Lung Large Cell Carcinoma · Lung Non-Squamous Non-Small Cell Carcinoma  ·  Sponsor: National Cancer Institute (NCI)

PhasePhase 2
Planned participants42
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This phase II trial tests whether TRC102 (methoxyamine hydrochloride) in combination usual care treatment comprised of pemetrexed, cisplatin or carboplatin, and radiation therapy followed by durvalumab works better than the usual care treatment alone to shrink tumors in patients with stage III non-squamous non-small cell lung cancer (NSCLC). TRC102 is in a class of drugs called antineoplastic agents. It blocks the ability of a cell to repair damage to its deoxyribonucleic acid (DNA) and may kill tumor cells. It may also help some anticancer drugs work better. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make DNA and may kill tumor cells. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy sources to kill tumor cells and shrink tumors. Giving TRC102 in combination with usual care treatment may be more effective than usual ca…

This description comes directly from the study's public registry record.

Talk to the study team

Contact details are listed per location below or on the registry record.

Always discuss trial participation with your own doctor first.

Locations (34)

Keck Medicine of USC Buena ParkBuena Park, California, United StatesRecruiting
City of Hope Comprehensive Cancer CenterDuarte, California, United StatesSuspended
City of Hope at Irvine LennarIrvine, California, United StatesSuspended
City of Hope Antelope ValleyLancaster, California, United StatesSuspended
Los Angeles General Medical CenterLos Angeles, California, United StatesRecruiting
USC / Norris Comprehensive Cancer CenterLos Angeles, California, United StatesRecruiting
USC Norris Oncology/Hematology-Newport BeachNewport Beach, California, United StatesRecruiting
University of California Davis Comprehensive Cancer CenterSacramento, California, United StatesActive Not Recruiting
City of Hope South PasadenaSouth Pasadena, California, United StatesRecruiting
City of Hope UplandUpland, California, United StatesSuspended
UM Sylvester Comprehensive Cancer Center at Coral GablesCoral Gables, Florida, United StatesRecruiting
UM Sylvester Comprehensive Cancer Center at Deerfield BeachDeerfield Beach, Florida, United StatesRecruiting

+ 22 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05198830